...
首页> 外文期刊>Cell & Bioscience >Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles
【24h】

Ferulic acid combined with aspirin demonstrates chemopreventive potential towards pancreatic cancer when delivered using chitosan-coated solid-lipid nanoparticles

机译:阿魏酸与阿司匹林联合使用壳聚糖包衣的固体脂质纳米颗粒给药后,显示出对胰腺癌的化学预防潜力

获取原文

摘要

Background The overall goal of this study was to demonstrate potential chemopreventive effects of ferulic acid (FA), an antioxidant, combined with aspirin (ASP), a commonly used anti-inflammatory drug for pancreatic cancer chemoprevention, using a novel chitosan-coated solid lipid nanoparticles (c-SLN) drug delivery system encapsulating FA and ASP. Results Our formulation optimization results showed that c-SLNs of FA and ASP exhibited appropriate initial particle sizes in range of 183?±?46 and 229?±?67?nm, encapsulation efficiency of 80 and 78?%, and zeta potential of 39.1 and 50.3?mV, respectively. In vitro studies were conducted to measure growth inhibition and degree of apoptotic cell death induced by either FA or ASP alone or in combination. Cell viability studies demonstrated combinations of low doses of free FA (200?μM) and ASP (1?mM) significantly reduced cell viability by 45 and 60?% in human pancreatic cancer cells MIA PaCa-2 and Panc-1, respectively. However, when encapsulated within c-SLNs, a 5- and 40-fold decreases in dose of FA (40?μM) and ASP (25?μM) was observed which was significant. Furthermore, increased apoptosis of 35 and 31?% was observed in MIA PaCa-2 and Panc-1 cells, respectively. In vivo studies using oral administration of combinations of 75 and 25?mg/kg of FA and ASP c-SLNs to MIA PaCa-2 pancreatic tumor xenograft mice model suppressed the growth of the tumor by 45?% compared to control, although this was not statistically significant. In addition, the immunohistochemical analysis of tumor tissue showed significant decrease in expression of proliferation proteins PCNA and MKI67, and also increased expression of apoptotic proteins p-RB, p21, and p-ERK1/2 indicating the pro-apoptotic role of the regimen. Conclusion Combination of FA and ASP delivered via a novel nanotechnology-based c-SLN formulation demonstrates potential for pancreatic cancer chemoprevention and could be a promising area for future studies.
机译:背景技术这项研究的总体目标是使用新型脱乙酰壳多糖包衣的固体脂质,证明抗氧化剂阿魏酸(FA)与阿司匹林(ASP)(一种常用的胰腺癌化学预防用消炎药)联合使用的潜在化学预防作用。包裹FA和ASP的纳米颗粒(c-SLN)药物输送系统。结果我们的配方优化结果表明,FA和ASP的c-SLNs的初始粒径在183?±?46和229?±?67?nm范围内,包封效率分别为80和78?%,ζ电位为39.1。和50.3?mV,分别。进行了体外研究以测量单独或联合使用FA或ASP诱导的生长抑制和凋亡细胞死亡的程度。细胞活力研究表明,低剂量的游离FA(200?μM)和ASP(1?mM)的组合可分别使人胰腺癌细胞MIA PaCa-2和Panc-1的细胞活力分别降低45%和60%。然而,当包裹在c-SLNs中时,观察到FA(40?μM)和ASP(25?μM)的剂量分别降低了5倍和40倍,这是显着的。此外,在MIA PaCa-2和Panc-1细胞中分别观察到35和31%的凋亡增加。对MIA PaCa-2胰腺肿瘤异种移植小鼠模型口服75和25?mg / kg FA和ASP c-SLNs组合口服给药的体内研究,与对照组相比,肿瘤的生长抑制了45%。没有统计学意义。此外,对肿瘤组织的免疫组织化学分析显示增殖蛋白PCNA和MKI67的表达显着降低,并且凋亡蛋白p-RB,p21和p-ERK1 / 2的表达也增加,表明该方案具有促凋亡作用。结论通过基于纳米技术的新型c-SLN制剂递送的FA和ASP的组合显示了胰腺癌化学预防的潜力,并且可能是未来研究的有希望的领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号